— Know what they know.
Not Investment Advice

COGT NASDAQ

Cogent Biosciences, Inc.
1W: +2.5% 1M: +0.5% 3M: -19.1% YTD: -7.9% 1Y: +111.6% 3Y: +262.5% 5Y: +262.5%
$32.01
+1.10 (+3.56%)
 
Weekly Expected Move ±5.4%
$28 $30 $31 $33 $35
NASDAQ · Healthcare · Biotechnology · Tech Score Neutral · Power 45 · $5.6B mcap · 156M float · 1.47% daily turnover · Short 57% of daily vol
Credit Risk of going bust: higher than 63% of companies Debt: 4.2% of company value Bonds: $38.2M held by 24 funds → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.23 (down 99.3%), Cogent Biosciences, Inc. would be worth roughly what it owes.
Total debt $244.3M against a stock market value of $5.55B.
Distance to default 4.01 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $113.2M (short-term plus half of long-term), stock volatility 90.6%; Altman Z'' -0.72. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.

📊 Key Metrics

TTM
$0M
Revenue
+0.0% YoY
$-377M
Net Income
-32.8% YoY
$-309M
Free Cash Flow
-31.8% YoY
0.0%
Gross Margin
0.0%
Op. Margin
0.0%
Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

⚠️ Cash Burn Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE-109.7%
ROA-68.0%
ROIC1964.0%

Valuation

P/E-13.9
P/B10.3
EV/EBITDA-16.3

Leverage

Debt/Equity0.46
Current Ratio13.57
Interest Cov.-72.7x

Quality Scores

Piotroski F3/9
Altman Z10.41
Beneish M0.00

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms